Supplemental material
Open access
6,625
Views
58
CrossRef citations to date
0
Altmetric
Reviews
Personalized medicine with biologics for severe type 2 asthma: current status and future prospects
Marie Godarargenx BVBA, Zwijnaarde, Belgium;VIB-UGent Center for Inflammation Research, Ghent, Belgium;Department of Internal Medicine, Ghent University, Ghent, Belgium
, Christophe Blanchetotargenx BVBA, Zwijnaarde, Belgium
, Hans de Haardargenx BVBA, Zwijnaarde, Belgium
, Bart N. LambrechtVIB-UGent Center for Inflammation Research, Ghent, Belgium;Department of Internal Medicine, Ghent University, Ghent, Belgium;Department of Pulmonary Medicine, ErasmusMC, Rotterdam, The Netherlands;Department of Epidemiology and Respiratory Medicine, ErasmusMC, Rotterdam, The NetherlandsCorrespondence[email protected] [email protected]
& Guy BrusselleDepartment of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium;Department of Epidemiology and Respiratory Medicine, ErasmusMC, Rotterdam, The NetherlandsCorrespondence[email protected] [email protected]
Pages 34-45
|
Received 22 Sep 2017, Accepted 11 Oct 2017, Published online: 14 Nov 2017
Related Research Data
Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma
Source:
Springer Science and Business Media LLC
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.